1. High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa H, et al. Hypertens Res. 2009;32:575-580.

2. Patients’ baseline characteristics Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.

3. Results

4. Summary The OSCAR study is the first large clinical trial to investigate the effect of high-dose ARB versus ARB plus CCB in high-risk elderly hypertensive patientsThe OSCAR study is the first large clinical trial to investigate the effect of high-dose ARB versus ARB plus CCB in high-risk elderly hypertensive patients Blood pressure was significantly lower in the ARB plus CCB group than in the high-dose ARB group.Blood pressure was significantly lower in the ARB plus CCB group than in the high-dose ARB group. There were no significant differences in primary end point rate, nor any differences in reducing CV events/non CV death between the groupsThere were no significant differences in primary end point rate, nor any differences in reducing CV events/non CV death between the groups In subgroup of patients with CV disease, primary end point rate was significantly higher in the high-dose ARB group than ARB plus CCB group (P=0.0261).In subgroup of patients with CV disease, primary end point rate was significantly higher in the high-dose ARB group than ARB plus CCB group (P=0.0261). Late-breaking clinical trial ACC 60th Annual Scientific session, April 5,2011, New Orleans.